Seek truth from facts, competitive symbiosis
Zhengqing Group has obtained registration and production approvals as well as clinical trial approvals for multiple pharmaceutical products.
Category:
Release time:
2026-03-06
Recently, our company has achieved a major breakthrough in pharmaceutical R&D and registration: four drug products have successfully obtained production registration approvals from the National Medical Products Administration, and one product has received clinical trial approval. These accomplishments underscore our strength and ongoing innovative capacity in the field of drug development, injecting strong momentum into the company’s high-quality growth.
Registration Production Approval:
Esomeprazole Enteric-Coated Capsules (available in 20 mg and 40 mg strengths);
Haloperidol raw material;
Mildodil topical solution;
Nafamostat mesylate raw material.
Clinical Approval:
Nafamostat Mesylate for Injection (available in 5 mg and 10 mg strengths)
The approval of multiple pharmaceutical products this time is the result of the company’s long-term commitment to drug R&D and its rigorous quality‑control measures. This not only enriches the company’s product portfolio and expands its business footprint but also provides clinicians with more safe and effective treatment options, helping to elevate the standard of care for related diseases and enabling the company to serve society and benefit patients with higher‑quality products.
Looking ahead, the company will continue to ramp up its R&D investment, accelerate the development, manufacturing, and market launch of a diverse portfolio of pharmaceutical products, remain committed to quality, deepen its expertise in the pharmaceutical and healthcare sectors, and drive higher‑quality growth.
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地